In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sinopharm Kicks Off National Emergency Allocation System For Medical Reserves

This article was originally published in PharmAsia News

Executive Summary

On the instruction of the National Development and Reform Commission, China National Pharmaceutical Group Corporation (Sinopharm) has shipped the first batch of ventilators, ECG monitors, surgical instruments and transfusion equipment to earthquake-hit regions in Sichuan. Responsible for national medical reserves, Sinopharm has set up an emergency allocation system and a group leading rescue efforts. All subsidiaries involved in the exercise are tasked to ensure the specifications and quantity of medical reserves correspond to NDRC's predetermined catalog, as well as make emergency procurement of necessary medicines and devices outside the catalog. Logistics centers in Beijing, Shanghai and Tianjin and major warehouses have been notified to stand by for medical allocation assignments at a moment's notice. (Click here for more - Chinese Language)

You may also be interested in...

Atox ‘Remains On Track’ Despite ACCUTE Setback

After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.

SillaJen Minority Shareholders Unite, Call For Trade Resumption

Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.

Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?

Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts